Damora Therapeutics (DMRA) Total Liabilities (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Total Liabilities data on file, last reported at $23.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 1339.55% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $23.8 million (up 1339.55% YoY), and the FY2025 full-year result was $20.1 million, up 1448.58% from the prior year.
• Total Liabilities for Q1 2026 stood at $23.8 million, up from $20.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $23.8 million in Q1 2026 and bottomed at $1.3 million in Q4 2024.
• The 5-year median for Total Liabilities is $7.6 million (2022), against an average of $8.6 million.
• The widest annual swing landed in 2024, when Total Liabilities tumbled 80.73%; it then surged 1448.58% in 2025.
• A 5-year view of Total Liabilities shows it stood at $11.4 million in 2022, then tumbled by 48.44% to $5.9 million in 2023, then sank by 77.93% to $1.3 million in 2024, then soared by 1448.58% to $20.1 million in 2025, then rose by 18.33% to $23.8 million in 2026.
• The last three Total Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.

Peer Comparison